SolAeroMed is the leader in biophysical
respiratory drugs and delivery devices.

Learn More


Asthma Rescue Drug & Delivery Device
In Phase II Clinical Trials


Surfactant Dysfunction
In Pre-Clinical Development


About SolAeroMed

SolAeroMed is a company dedicated to the development of novel therapeutic strategies to treat obstructive lung diseases. Our lead asthma drug, S-1226, is in Phase II clinical trials designed to demonstrate Proof of Concept.


SolAeroMed management and clinicians have a number of upcoming conferences it will be attending. Please visit our News & Events page for more details.

SolAeroMed is seeking development partners for their
novel Asthma and Surfactant Dysfunction products.

Learn More